About PPD
Sponsored by Sage Therapeutics, Inc., and Biogen Inc. Important Safety Information Prescribing Information It’s time to talk to your adult patients about postpartum depression (PPD) IMPORTANT SAFETY INFORMATION WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage […]
Introducing ZURZUVAE
Sponsored by Sage Therapeutics, Inc., and Biogen Inc. Important Safety Information Prescribing Information Indicated for adults with postpartum depression (PPD) Discover a groundbreaking 14-day treatment course for postpartum depression1 IMPORTANT SAFETY INFORMATION WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. […]
Clinical Trial Data
Patient Identification
Getting Patients Started
Dosing and Prescribing
Screening
For Your Patients
Patient Identification
Sponsored by Sage Therapeutics, Inc., and Biogen Inc. Important Safety Information Prescribing Information Consider ZURZUVAE for adult patients like these with postpartum depression (PPD) IMPORTANT SAFETY INFORMATION WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage […]
Getting Patients Started
Sponsored by Sage Therapeutics, Inc., and Biogen Inc. Important Safety Information Prescribing Information How to get your adult patients with postpartum depression (PPD) started on ZURZUVAE IMPORTANT SAFETY INFORMATION WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not […]
